Ethris announces promising phase 1 results for ETH47, its mRNA therapy for uncontrolled asthma. The inhaled treatment showed strong safety and efficacy, with plans for a phase 2 trial in 2025.
(Alliance News) - GSK PLC on Tuesday said applications for its treatment for a type of asthma and chronic rhinosinusitis with nasal polyps, or CRSwNP, have been accepted for review in China, Japan and ...
Anti-IL-4Rα monoclonal antibodies are among the best-selling biologics in this field. MG-K10 is an innovative long-acting anti-IL-4Rα humanizedmonoclonal antibody that simultaneously blocks the ...
has a place in the effort to avert acute attacks; however, its use is restricted within the allergic asthma subtype. The treatment of an already established exacerbation is more straight forward ...
Therapeutic Use Exemption (TUE) Physician Guidelines - on Asthma. All TUE Physician Guidelines are reviewed annually by WADA's TUE Expert Advisory Group to ensure that they remain consistent with good ...